Overview

Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2013-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to observe the Efficacy and safety of 400 μg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Phase:

Phase 3

Details

Lead Sponsor:

Daewoong Pharmaceutical Co. LTD.

Treatments:

Bromides